page_banner

products

Thrombus Chemiluminescense Immunoassay Kit

short description:

Thrombotic disease – a general term for various diseases such as lesions, necrosis, dysfunction and damage of corresponding organs and tissues caused by vascular blockage caused by thrombosis. Conditions of thrombosis: vascular endothelial injury, circulation stasis, hypercoagulability.


  • FOB Price: US $0.5 - 9,999 / Piece
  • Min.Order Quantity: 100 Piece/Pieces
  • Supply Ability: 10000 Piece/Pieces per Month
  • Product Detail

    Product Tags

    Chemiluminescent Solution(General Items)

    Series

    Product Name

    Product Name

    Thrombus

    Thrombin-Antithrombin Complex

    TAT

    Plasmin -Antiplasmin Complex

    PIC

    Thrombomodulin

    TM

    Tissue Plasminogen Activator Inhibitor Complex

    t-PAIC

    Fibrin(-ogen) Degradation Products

    FDP

    D-Dimer

    D-Dimer

    Thrombotic disease – a general term for various diseases such as lesions, necrosis, dysfunction and damage of corresponding organs and tissues caused by vascular blockage caused by thrombosis. Conditions of thrombosis: vascular endothelial injury, circulation stasis, hypercoagulability.

    The six molecular markers of thrombus (TAT/PIC/t-PAIC/TM/DD/FDP) involve coagulation, fibrinolysis and vascular endothelial system. Thrombin is a key factor in the coagulation system. When the coagulation system is activated, Prothrombin is converted into thrombin. Since the thrombin has a very short half-life period of only a few seconds in blood and is quickly neutralized by antithrombin, Therefore, detection of thrombin antithrombin complex (TAT) can directly reflect thrombin production. The prelude of thrombus formation is the activation of the coagulation system and the consumption of the anticoagulant system. Therefore, TAT detection can predict the formation of thrombus and the recurrence of rethrombus at an early stage.

    When the fibrinolytic system is activated, plasminogen is converted to plasmin, which degrades fibrin to form FDP and DD. The α2 plasmin inhibitor (α2PI) produced by liver is the most important inhibitor of plasmin. The α2 plasmin inhibitor rapidly binds to the plasmin in blood at a rate of 1:1 to form the plasmin-α2 plasmin inhibitor complex (PIC) to inhibit fibrinolysis. Therefore, PIC is a molecular marker of plasmin that faithfully reflects the final stage of fibrinolytic system. It is one of the important indexes of thrombolytic therapy and prevention of rethrombolysis.

    Tissue plasminogen activator (t-PA) produced by vascular endothelial cells converts plasminogen produced and released into the blood by liver to plasmin. Tissue-type plasminogen activator released into the blood by vascular endothelial cells rapidly binds to the plasminogen activator inhibitor-1 (PAI-1) in a 1:1 manner to form tissue-type plasminogen activator-plasminogen activator inhibitor-1 complex (t-PAIC). An increase in the t-PAIC complex means an increase in the concentration of tissue-type plasminogen activator in the blood, which can be considered a molecular marker of both the fibrinolytic system and vascular endothelial cell damage.

    Thromboregulatory protein (TM) is one of the markers of vascular endothelial cell damage. TM not only combines with thrombin to exert antithrombin effect, thrombin -TM complex actively activates clotting inhibitor protein C, but also exerts anticoagulation effect.

    From the diagram of action mechanism, we can see that these molecular markers are generated at the initial stage of response of each system, so they can be used as early indicators of disease.


  • Previous:
  • Next:

  • HOME